# Peptides in 2 — Episode 13: Eloralintide

Natural-pace revision. Evidence cutoff October 14, 2026. Published October 14, 2026.

Fresh neutral Tom recording at normal generation speed, including the closing. No speech speed adjustment or time-stretching. The fuller original script is restored; scene timing follows the recording. A brief line, “Weight loss is only part of the picture. Tolerability matters too,” fills the former silent gap after the estimates, using the same narrator and normal speed. No music or older closing recording. Four original artworks and exact result graphics are retained. Runtime: 113 seconds, under two minutes.

## Sequence

| Seconds | Visual |
|---|---|
| 0.00–2.00 | WPF opening |
| 2.00–16.34 | Identity and developer |
| 16.34–30.08 | Receptor selectivity and discovery credits |
| 30.08–37.80 | Laboratory evidence and clinical questions |
| 37.80–53.92 | Clinical trial population and investigators |
| 53.92–75.14 | Weight-loss estimates and tolerability transition |
| 75.14–87.70 | Adverse events and interpretation |
| 87.70–106.39 | Investigational status, next film and closing insight |
| 106.39–113.00 | WPF closing; brief final hold |

## Materials and validation

MP4, source pack, full scientific notes, transcript, captions, thumbnail and website copy. Verify original recording duration is preserved, all eight speech sections reach the export, the closing is complete, chart values and artwork are unchanged, captions match and the complete movie decodes.

Closing revision: “The next chapter depends on longer-term evidence.” precedes the WPF closing. Original speech remains at normal recorded pace; the final hold is shortened.